Aug. 26 at 5:52 PM
LLY reported Phase 3 ATTAIN-2 data for oral obesity treatment orforglipron in 1,600+ adults with obesity/overweight and type 2 diabetes. The trial met its primary endpoint, showing 9.6% weight loss at 36mg vs. 2.5% placebo over 72 weeks, and achieved all key secondary endpoints, including A1C reduction and cardiometabolic improvements.
Barclays notes results are broadly in line with expectations, competitive with Wegovy (STEP-2), and could reignite investor interest in oral treatments. Clearance paves the way for potential 2026 launch, with orforglipron potentially advantaged over 25mg oral semaglutide due to scalability without fasting.
$BCS $LLY